Insulin resistance and postmenopausal hormone replacement therapy

Metabolic Syndrome and Related Disorders

Volumn 2, Issue 4, 2004, Pages 234-240

  Saglam, Kenan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

20ALPHA DIHYDROPROGESTERONE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GLUCOSE; INSULIN; LEVONORGESTREL; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE;

ARTICLE; BILIARY TRACT DISEASE; CARBOHYDRATE METABOLISM; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; FIRST PASS EFFECT; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEART PROTECTION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THROMBOEMBOLISM;

EID: 20544441719     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2004.2.234     Document Type: Article

References (41)

1. Lindheim SR, Notelovitz M, Feldman EB, Larsen J, Khan FY, Lobo RA. The independent effects of exercise and estrogen on lipids and lipoproteins in postmenopausal women. Obstet Gynecol 1994;83:167-172.
2. Saglam K, Polat Z, Gulec M, Yilmaz MI. Effects of postmenopausal hormone replacement treatment to insulin resistance. Endocrinology 2002;18:211-214.
3. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17β-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 1997;104:298-304.
4. Proudler AJ, Felton CV, Stevenson JC. Ageing and response of plazma insulin, glucose and c-peptide concentrations to intravenous glucose in postmenopausal women. Clin Sci (Lond) 1992;83:489-494.
5. Raudaskoski T, Tomas C, Laatikanen T. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel. Acta Obstet Gynecol Scand 1999;78: 540-545.
6. Cefalu WT, Wagner JD, Bell-Farrow AD, Wang ZQ, Adams MR, Toffolo G, Cobelli C. The effects of hormonal replacement therapy on insulin sensitivity in surgical postmenopausal cynomolgus monkeys (Macaca fascicularis). Am J Obstet Gynecol 1994;17:440-445.
7. Ongphiphadhanakul B, Thamprajanmchit S, Chanprasertyothin S, Chailurkit L, Rajatanavin R. Effect of estrogen replacement on insulin sensitivity, serum lipid and bone resorption marker in hypogonadal males. Maturitas 2002;42:85-89.
8. Seed M, Sands RH, McLaren M, Kirk G, Darko D. The effect of hormone replacement therapy and rout of administration on select cardiovascular risk factors in postmenopausal women. Fam Pract 2000;17: 497-507.
9. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system. Nonlipid effects. Drugs 1994;47(Suppl 2):35-41.
10. Sumino H, Ichikawa S, Itoh H, Utsugi T, Ohyama Y, Umeda M, Nakamura T, Kanda T, Mizunuma H, Tomono S, Murakami M, Kurabayashi M. Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance. Horm Res 2003;60:134-142.
11. Li C, Samsioe G, Borgfeldt C, Bendahl P, Wilawan K, Aberg A. Low-dose hormone therapy and carbohydrate metabolism. Fertil Steril 2003;79:550-555.
12. Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, Whitehead MI, Wynn V. Comprasion of transdermal and oral estrogen/progestrone hormone replacement therapy effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950-955.
13. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum and lipoproteins in healthy women. Atherosclerosis 1993;98:83-90.
14. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA 1993;269:3015-3023.
15. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plazma lipoproteins. N Engl J Med 1991;325:1196-1204.
16. Ozsener S. Hormon replasman tedavisi. T Klin Endokrin 2003;1:148-156.
17. Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimes on hearts disease risk factors in postmenopausal women. The postmenopausal estrojen/progestin interventions (PEPI) trial. JAMA 1995;273:199-208.
18. Medical Research Council's General Practice Framework. Randomised comparison of oestrogen versus oestrogen plus progesterone replacement therapy in women with hysterectomy. BMJ 1996;312:473-478.
19. Prelevic GM, Jacobs HS. Menopause and postmenopause. Baillieres Clin Endocrinol Metab 1997;11:311-340.
20. Bush TL, Barett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiyovasculer mortality and noncontraceptive use of estrogen in women: Results from the lipid research clinics program follow-up study. Circulation 1987;75:1102-1109.
21. Stampfer M, Colditz G, Willet W, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten years follow up from the Nurses' Health Study. N Engl J Med 1991;325:756-762.
22. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of and progestin in postmenapausal. women. Arch Intern Med 1994;154:1333-1339.
23. Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease. Effect on survival in postmenapausal women. Arch Intern Med 1990;150:2557-2562.
24. Vittinghoff E, Shlipak MG, Varosy PD, Furberg CD, Ireland CC, Khan SS, Blumenthal R, Barrett-Connor E, Huley S. Risk factor and secondary prevention in women with heart disease: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2003; 138:81-89.
25. Lemay A. The relevans of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice. J Obstet Gynaecol Can 2002; 24:683-689.
26. Skouby So. Consequenses for HRT following the HERS II and WHI reports: the primum non nocere is important, but translation into quo vadis is even more essential. Acta Obstet Gynaecol Scand 2002;81: 793-798.
27. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insülin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest 1987;79: 790-800.
28. De Fronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
29. Starke AA. Determation of insuline sensitivity: Methodological considerations. J Cardiovasc Pharmacol 1992;20(Suppl.11):1-21.
30. Spellacy WN. Menopause, estrogen treatment and carbohydrate metabolism. In: Mishell DR, ed. Menopause: Physiology and Pharmacology. Chicago: Year Book Medical, 1987:253-260.
31. Cucinelli F, Soranna L, Perri C, Romualdi D, Barini A, Mancuso S, Lanzone A. Naloxone decreases insulin secretion in hyperinsulinemic postmenopausal women and may positively affect hormone replacement therapy. Fertil Steril 2002;78:1017-1024.
32. Manassiev NA, Godsland IF, Crook D, Proudler AJ, Whitehead MI, Stevenson JC. Effect of postmenopausal oestradiol and dydregesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women. Maturitas 2002;42:233-242.
33. Elkind-Hirsch KE, Sherman LD, Malinak R. Hormone replacement therapy alters insülin sensitivity in young women with premature ovarian failure. J Clin Endocrinol Metab 1993;76:472-475.
34. Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA, Bush TL. Effect of postmenopausal hormone therapy on glucose and insülin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998; 21:1589-1595.
35. Fineberg SE. Glycaemic control and hormone replacement therapy: implications of the Postmenauposal Estrogen/Progesteron Intervention (PEPI) study. Drugs Aging 2000;17:453-456.
36. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997;11:41-355.
37. Crook D, Cust M, Gangar K, Worthington M, Hillard T, Stevenson JC, Whitehead M, Wynn V. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950-955.
38. Godsland IF, Gangar K, Walton C, Cust M, Whitehead M, Wynn V, Stevenson JC. Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-853.
39. Lasco A, Alvaro S, Frisina N, Benedetto A, Denuzo G, Cucinotta D. Long-term transdermal estrogen therapy improves lipid profile but not insulin resistance in healty postmenopausal women. Diabetes Care 2000;23:422-424.
40. Soranna L, Cucinelli F, Perri C, Muzj G, Giuliani M, Lanzone A. Individual effect of E2 and dydrogesteron on insulin sensitivity in postmenopausal woman. J Endocrinol Invest 2002;25:547-550.
41. Baziad A, Pache T. Cardiovascular disease and hormone replacement therapy. First consensus meeting on menopause in the east Asian region, eds. Ratnam SS, Campana A. Geneva, 26-30 May, 1997.